Tisotumab Vedotin Treatment for Recurrent or Metastatic Cervical Cancer: Positive Results in Phase II Clinical Trials
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The objective response rate to standard treatment in patients with recurrent or metastatic cervical cancer is usually less than 15%, with a median total survival of between 6.0 and 9.4 monthsSeattle Genetics today released the top-line results of a Phase II single-arm clinical trial called InnovaTV 204, which assessed the effectiveness and safety of tisotumab vedotin treatment for recurrent or metastatic cervical cancer, which is administered every three weeksThe results showed that the patient's objective remission rate (ORR) was 24% and the median duration of the remission (DOR) was 8.3 monthsThe most common adverse events associated with treatment (greater than or equal to 20%) include hair loss, nosebleeds, nausea, conjunctivitis, fatigue and dry eye diseaseTisotumab vedotin is a research antibody-drug conjugate (ADC) that targets factors that are expressed in cervical cancer cells and promote tumor growthRoger Dansey, chief medical officer at Seattle Genetics, said: "Patients with recurrent or metastatic cervical cancer have limited the treatment available as the disease progressesTisotumab vedotin has shown significant clinical significance and lasting objective response."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
